Evidence map›Paper›PMID 26596237›Full record

Observational studyBMC neurology2015

The ThRombolysis in UnconTrolled Hypertension (TRUTH) protocol: an observational study on treatment strategy of elevated blood pressure in stroke patients eligible for IVT.

T P Zonneveld, A Algra, D W J Dippel, L J Kappelle, R J van Oostenbrugge, Y B W E M Roos, M J Wermer, H B van der Worp, P J Nederkoorn, N D Kruyt and 1 more

Abstract readObservational Study
In one paragraph

Observational study in BMC neurology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Blood Pressure Management in Acute Ischemic Stroke.Current hypertension reports · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

T P ZonneveldDepartment of Neurology, Academic Medical Center, Amsterdam, The Netherlands. t.p.zonneveld@amc.uva.nl.
A AlgraDepartment of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands. a.algra@umcutrecht.nl.
D W J DippelDepartment of Neurology, Erasmus Medical Center, Rotterdam, The Netherlands. d.dippel@erasmusmc.nl.
L J KappelleDepartment of Neurology and Neurosurgery, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, The Netherlands. l.kappelle@umcutrecht.nl.
R J van OostenbruggeDepartment of Neurology, Maastricht UMC+, Maastricht, The Netherlands. r.van.oostenbrugge@mumc.nl.
Y B W E M RoosDepartment of Neurology, Academic Medical Center, Amsterdam, The Netherlands. y.b.roos@amc.uva.nl.
M J WermerDepartment of Neurology, Leiden University Medical Center, Leiden, The Netherlands. m.j.h.wermer@lumc.nl.
H B van der WorpDepartment of Neurology and Neurosurgery, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, The Netherlands. h.b.vanderworp@umcutrecht.nl.
P J NederkoornDepartment of Neurology, Academic Medical Center, Amsterdam, The Netherlands. p.j.nederkoorn@amc.uva.nl.
N D KruytDepartment of Neurology, Leiden University Medical Center, Leiden, The Netherlands. ndkruyt@gmail.com.
TRUTH investigators

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIntravenous thrombolysis (IVT) with (recombinant) tissue plasminogen activator is an effective treatment in acute ischemic stroke. However, IVT is contraindicated when blood pressure is above 185/110 mmHg, because of an increased risk on symptomatic intracranial hemorrhage. In current Dutch clinical practice, two distinct strategies are used in this situation. The active strategy comprises lowering blood pressure with antihypertensive agents below these thresholds to allow start of IVT. In the conservative strategy, IVT is administered only when blood pressure drops spontaneously below protocolled thresholds. A retrospective analysis in two recent stroke trials showed a non-significant signal towards better functional outcome in the active group; robust evidence for either strategy, however, is lacking. We hypothesize that (I) the active strategy leads to a better functional outcome three months after acute ischemic stroke. Secondary hypotheses are that this effect occurs despite (II) increasing the number of symptomatic intracranial hemorrhages, and could be attributable to (III) a higher rate of IVT treatments and (IV) a shorter door-to-needle time. METHODS AND

designThe TRUTH is a prospective, observational, cluster-based, parallel group follow-up study; in which participating centers continue their current local treatment guidelines. Outcomes of patients admitted to centers with an active will be compared to those admitted to centers with a conservative strategy. The primary outcome is functional outcome on the modified Rankin Scale at three months. Secondary outcomes are symptomatic intracranial hemorrhage, IVT treatment and door-to-needle time. We based our sample size estimate on an ordinal analysis of the mRS with the "proportional odds" model. With the aforementioned signal observed in a recent retrospective study in these patients as an estimate of the effect size and with alpha 0 · 05, this analysis would have an 80 % power with a total number of 600 patients. Corrections for expected imbalance in group size and clustering effects resulted in a sample size of 1235 patients. DISCUSSION: The TRUTH is the first large prospective study specifically studying IVT-candidates with elevated blood pressure, and has the potential to change clinical practice and optimize acute stroke care in these patients.

Indexed as

Administration, IntravenousAntihypertensive AgentsBlood PressureBrain IschemiaFibrinolytic AgentsFollow-Up StudiesHumansHypertensionIntracranial HemorrhagesProspective StudiesStrokeThrombolytic TherapyTissue Plasminogen ActivatorAntihypertensive AgentsFibrinolytic AgentsTissue Plasminogen Activator

Identifiers

PMID26596237
PMCPMC4657238

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.